This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
News|Articles|March 25, 2026
Promise, Pitfalls, and Progress of Price Transparency in US Health Care: John Barkett
Author(s)Pearl Steinzor
Fact checked by: Julia Bonavitacola
Making health care prices public was supposed to cut costs. The reality is more complicated.
Advertisement
Advertisement
Price transparency was sold as one of health care’s simple fixes. The aim was to show patients and employers what insurers actually pay for their care, allowing market forces to do the rest.
Related to this article
With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.
Advertisement
Advertisement